Unigene Accelerates Development of Anorexigenic Peptide

The lead satiety compound from Unigene, UGP281 has already demonstrated substantial decreases in food consumption in preclinical studies. Most peptides on the market require injection and there are no oral peptide therapeutic products as oral delivery has been hindered by low absorption and degradation in the gastro-intestinal tract.